kidney disease Archives -

Sanofi’s venglustat bombs again, but isn’t dead yet

https://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/

FDA sets September review date for Calliditas’ rare kidney disease drug

https://pharmaphorum.com/news/fda-sets-september-review-date-for-calliditas-rare-kidney-disease-drug/

Calliditas eyes 2022 approval in EU for rare kidney disease drug Nefecon

https://pharmaphorum.com/news/calliditas-eyes-2022-approval-in-eu-for-rare-kidney-disease-drug-nefecon/

Pharma poised to cash in on ‘long COVID’ symptoms

https://pharmaphorum.com/news/big-pharma-could-cash-in-on-long/

Ardelyx’s ambition to revolutionise kidney treatment

https://pharmaphorum.com/r-d/views-analysis-r-d/ardelyxs-ambition-to-revolutionise-kidney-treatment/

Mallinckrodt’s liver disease drug terlipressin edges FDA advisory panel

https://pharmaphorum.com/news/mallinckrodts-liver-disease-drug-terlipressin-edges-fda-advisory-panel/

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

https://pharmaphorum.com/events/3rd-chronic-kidney-disease-drug-development-ckd3-summit-2/

3rd Chronic Kidney Disease Drug Development (CKD3) Summit

https://pharmaphorum.com/events/3rd-chronic-kidney-disease-drug-development-ckd3-summit/

Q&A: Novartis’ Eric Hughes on transplantation

https://pharmaphorum.com/r-d/views-analysis-r-d/novartis-eric-hughes-transplantation/

Search